Patterns of Relapse in High-Risk Neuroblastoma Patients Treated With and Without Total Body Irradiation

被引:23
|
作者
Li, Richard [1 ,2 ]
Polishchuk, Alexei [3 ]
DuBois, Steven [1 ,4 ]
Hawkins, Randall [3 ]
Lee, Stephanie W. [2 ]
Bagatell, Rochelle [5 ]
Shusterman, Suzanne [1 ,4 ]
Hill-Kayser, Christine [6 ]
Al-Sayegh, Hasan [2 ,4 ]
Diller, Lisa [1 ,4 ]
Haas-Kogan, Daphne A. [1 ,2 ,4 ]
Matthay, Katherine K. [3 ]
London, Wendy B. [1 ,4 ]
Marcus, Karen J. [1 ,2 ,4 ]
机构
[1] Harvard Med Sch, Boston, MA USA
[2] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
[3] Univ Calif San Francisco, Sch Med, San Francisco, CA USA
[4] Dana Farber Boston Childrens Canc & Blood Disorde, Boston, MA USA
[5] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA
[6] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA
关键词
STEM-CELL TRANSPLANTATION; BONE-MARROW-TRANSPLANTATION; CHILDRENS ONCOLOGY GROUP; EXCELLENT LOCAL-CONTROL; HIGH-DOSE CHEMOTHERAPY; INRG TASK-FORCE; RADIATION-THERAPY; INTENSIVE CHEMOTHERAPY; REFRACTORY NEUROBLASTOMA; GROUP PROJECT;
D O I
10.1016/j.ijrobp.2016.10.047
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: External beam radiation therapy to initial sites of disease may influence relapse patterns in high-risk neuroblastoma. However, the effect of systemic irradiation by use of total body irradiation (TBI) on anatomic patterns of relapse has not previously been investigated. Methods and Materials: We retrospectively analyzed patients receiving definitive treatment of high-risk neuroblastoma with subsequent relapse in bony metastatic sites, with a date of relapse between January 1, 1997, and December 31, 2012. Anatomic sites of disease, defined by metaiodobenzylguanidine (MIBG) avidity, were compared at diagnosis and at first relapse. The Fisher exact test was performed to compare relapse in initially involved sites between patients treated with and without TBI. Results: Seventy-four patients with a median age at diagnosis of 3.5 years (range, 0.3-15.3 years) had relapse in 227 sites of MIBG-avid metastatic disease, with a median time to relapse of 1.8 years. Of the 227 sites of first relapse, 154 sites (68%) were involved at diagnosis. When we compared relapse patterns in patients treated with and without TBI, 12 of 23 patients (52%) treated with TBI had relapse in >= 1 previously MIBG-avid site of disease whereas 40 of 51 patients (78%) treated without TBI had relapse in >= 1 previously MIBG-avid site of disease (P = .03). Conclusions: Patients treated with systemic irradiation in the form of TBI were significantly less likely to have relapse in prior sites of disease. These findings support further investigation into the role of radiopharmaceutical therapies in curative multi-modality therapy. (C) 2016 Elsevier Inc. All rights reserved.
引用
收藏
页码:270 / 277
页数:8
相关论文
共 50 条
  • [1] PATTERNS OF RELAPSE IN HIGH-RISK NEUROBLASTOMA PATIENTS
    Li, R.
    Sridharan, M.
    London, W.
    Lee, S.
    Shusterman, S.
    Marcus, K.
    PEDIATRIC BLOOD & CANCER, 2014, 61 : S208 - S208
  • [2] Patterns of Failure in High-Risk Neuroblastoma with or without Metastatic Site Irradiation
    Aliru, M. L.
    Chapman, J. T.
    Montalvo, S. K.
    Dan, T.
    Watt, T. C.
    Kumar, K. A., Jr.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : E487 - E487
  • [3] Patterns of relapse after immunotherapy in patients with high-risk neuroblastoma.
    Moerdler, Scott
    Naranjo, Arlene
    Tenney, Sheena
    Bagatell, Rochelle
    Yu, Alice L.
    London, Wendy B.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [4] Late effects in survivors of high-risk neuroblastoma following stem cell transplant with and without total body irradiation
    Hobbie, Wendy L.
    Li, Yimei
    Carlson, Claire
    Goldfarb, Samuel
    Laskin, Benjamin
    Denburg, Michelle
    Goldmuntz, Elizabeth
    Mostoufi-Moab, Sogol
    Wilkes, Jennifer
    Smith, Karen
    Sacks, Nancy
    Szalda, Dava
    Ginsberg, Jill P.
    PEDIATRIC BLOOD & CANCER, 2022, 69 (03)
  • [5] Patterns and Outcomes of Relapse Treated With Radiotherapy Following Total Marrow and Lymphoid Irradiation in High-Risk and/or Relapsed/Refractory Acute Leukemia
    Ladbury, C. J.
    Semwal, H.
    Hong, D.
    Yang, D.
    Marcucci, G.
    Nakamura, R.
    Al Malki, M.
    Rosenthal, J.
    Stein, A.
    Hui, S. K.
    Ali, H.
    Wong, J. Y. C.
    Dandapani, S. V.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : S80 - S81
  • [6] Relapse patterns after local and residual metastatic irradiation in high risk neuroblastoma
    Recalde, E.
    Ramos, M.
    Mico, S.
    Giralt, J.
    RADIOTHERAPY AND ONCOLOGY, 2023, 182 : S287 - S287
  • [7] WHOLE NEURAXIS IRRADIATION TO ADDRESS CENTRAL NERVOUS SYSTEM RELAPSE IN HIGH-RISK NEUROBLASTOMA
    Croog, Victoria J.
    Kramer, Kim
    Cheung, Nai-Kong V.
    Kushner, Brian H.
    Modak, Shakeel
    Souweidane, Mark M.
    Wolden, Suzanne L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (03): : 849 - 854
  • [8] Survival in patients with high-risk neuroblastoma treated without autologous stem cell transplant or dinutuximab beta
    Jain, Richa
    Trehan, Amita
    Menon, Prema
    Kapoor, Rakesh
    Kakkar, Nandita
    Radhika, Srinivasan
    Saxena, Akshay Kumar
    Mittal, Bhagwant Rai
    Varma, Neelam
    Samujh, Ram
    Bansal, Deepak
    PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2021, 38 (04) : 291 - 304
  • [9] Patterns of improvement following initial response in patients treated with naxitamab for relapsed/refractory high-risk neuroblastoma
    Mora, Jaume
    Chan, Godfrey C.
    Morgenstern, Daniel A.
    Amoroso, Loredana
    Nysom, Karsten
    Faber, Joerg
    Wingerter, Arthur
    Bear, Melissa
    Rubio-San-Simon, Alba
    Tornoe, Karen
    Duering, Maria
    Kushner, Brian H.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [10] Patterns of Locoregional Relapse after Radiotherapy for High-Risk Neuroblastoma: A Multi-Institutional Study
    Liu, K. X.
    Shaaban, S.
    Lerman, B. J.
    Chen, J. J.
    Bagatell, R.
    Dubois, S. G.
    Shusterman, S.
    Ioakeim-Ioannidou, M.
    Yock, T. I.
    Dusenbery, K. E.
    Vo, K. T.
    Huang, M.
    Friedmann, A.
    Diller, L. R.
    Marcus, K. J.
    MacDonald, S.
    Terezakis, S. A.
    Braunstein, S. E.
    Hill-Kayser, C. E.
    Haas-Kogan, D. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : E488 - E488